{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:00:35Z","timestamp":1759334435509,"version":"build-2065373602"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"York Research Chair in Population Health Ethics & Law","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["221719"],"award-info":[{"award-number":["221719"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Collaborative Bioscience Innovation & Law Programme","award":["NNF23SA0087056"],"award-info":[{"award-number":["NNF23SA0087056"]}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1004736","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:21:01Z","timestamp":1759252861000},"page":"e1004736","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Whose burden, whose benefit? Revisiting ethical trade-offs in the WHO guidelines on scaling up mass azithromycin administration"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-5385","authenticated-orcid":true,"given":"Maple","family":"Goh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2379-4523","authenticated-orcid":true,"given":"A. M.","family":"Viens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safura","family":"Abdool Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-2666","authenticated-orcid":true,"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Outterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"3","key":"pmed.1004736.ref001","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4269\/ajtmh.18-0846","article-title":"Mass azithromycin distribution to prevent childhood mortality: a pooled analysis of cluster-randomized trials","volume":"100","author":"CE Oldenburg","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"pmed.1004736.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010853","article-title":"Individual longitudinal compliance to neglected tropical disease mass drug administration programmes, a systematic review","volume":"17","author":"R Maddren","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"23","key":"pmed.1004736.ref003","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1817213","article-title":"Longer-term assessment of azithromycin for reducing childhood mortality in Africa","volume":"380","author":"JD Keenan","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"pmed.1004736.ref004","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-002446","article-title":"Mass azithromycin administration: considerations in an increasingly resistant world","volume":"5","author":"Y Hooda","year":"2020","journal-title":"BMJ Glob Health"},{"issue":"8","key":"pmed.1004736.ref005","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa2312093","article-title":"Azithromycin to reduce mortality\u2014an adaptive cluster-randomized trial","volume":"391","author":"KS O\u2019Brien","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"pmed.1004736.ref006","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa1715474","article-title":"Azithromycin to reduce childhood mortality in sub-Saharan Africa","volume":"378","author":"JD Keenan","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"pmed.1004736.ref007","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/jac\/dkaf092","article-title":"Biannual azithromycin mass drug administration for reduction of childhood mortality: a systematic review and meta-analysis","volume":"80","author":"MP Gurunthalingam","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"71","key":"pmed.1004736.ref008","article-title":"Mass administration of azithromycin to infants does not promote their survival in Mali [version 1]","volume":"2","author":"F Haidara","year":"2025","journal-title":"VeriXiv"},{"issue":"3","key":"pmed.1004736.ref009","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.4269\/ajtmh.19-0622","article-title":"Cost-effectiveness of mass treatment with azithromycin for reducing child mortality in Malawi: secondary analysis from the MORDOR trial","volume":"103","author":"JD Hart","year":"2020","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"pmed.1004736.ref010","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100054","article-title":"Neonatal azithromycin administration for prevention of infant mortality","volume":"1","author":"CE Oldenburg","year":"2022","journal-title":"NEJM Evid"},{"issue":"3","key":"pmed.1004736.ref011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa2309495","article-title":"Azithromycin during routine well-infant visits to prevent death","volume":"390","author":"A Si\u00e9","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004736.ref012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s40249-022-01023-6","article-title":"Ethical challenges in mass drug administration for reducing childhood mortality: a qualitative study","volume":"11","author":"A Alasmar","year":"2022","journal-title":"Infect Dis Poverty"},{"issue":"7","key":"pmed.1004736.ref013","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/cid\/ciz893","article-title":"Antimicrobial resistance following azithromycin mass drug administration: potential surveillance strategies to assess public health impact","volume":"70","author":"I Mack","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pmed.1004736.ref014","article-title":"Impact of azithromycin mass drug administration on the antibiotic-resistant gut microbiome: a randomized, controlled trial","author":"H Pickering","year":"2021","journal-title":"medRxiv"},{"issue":"10459","key":"pmed.1004736.ref015","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","author":"GBD 2021 Antimicrobial Resistance Collaborators","year":"2024","journal-title":"Lancet"},{"key":"pmed.1004736.ref016","first-page":"1","article-title":"Drug-resistant infections: a threat to our economic future","volume":"2","author":"OB Jonas","year":"2017","journal-title":"World Bank Rep"},{"volume-title":"Global antimicrobial resistance and use surveillance system (GLASS) report 2022","year":"2022","author":"World Health Organization","key":"pmed.1004736.ref017"},{"issue":"23","key":"pmed.1004736.ref018","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMc1901535","article-title":"Macrolide resistance in MORDOR I: a cluster-randomized trial in Niger","volume":"380","author":"T Doan","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"pmed.1004736.ref019","article-title":"Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review","volume":"19","author":"KS O\u2019Brien","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"pmed.1004736.ref020","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/cid\/cit137","article-title":"Mass distribution of azithromycin for trachoma control is associated with increased risk of azithromycin-resistant Streptococcus pneumoniae carriage in young children 6 months after treatment","volume":"56","author":"CL Coles","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pmed.1004736.ref021","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.4269\/ajtmh.18-0747","article-title":"A cross-sectional study of the availability of azithromycin in local pharmacies and associated antibiotic resistance in communities in Kilosa District, Tanzania","volume":"100","author":"D Ansah","year":"2019","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"pmed.1004736.ref022","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/ije\/dyu062","article-title":"Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control","volume":"43","author":"JC Seidman","year":"2014","journal-title":"Int J Epidemiol"},{"key":"pmed.1004736.ref023","article-title":"Long-term effects of azithromycin mass administration to reduce childhood mortality on Streptococcus pneumoniae antimicrobial resistance: a population-based, cross-sectional, follow-up carriage survey","author":"A Kalizang\u2019oma","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pmed.1004736.ref024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40249-025-01322-8","article-title":"Mass drug administration trials of azithromycin: an analysis to inform future research and guidelines","volume":"14","author":"AC Kong","year":"2025","journal-title":"Infect Dis Poverty"},{"volume-title":"WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival","year":"2020","author":"World Health Organization","key":"pmed.1004736.ref025"},{"volume-title":"Public notice and comment process on WHO Guideline on mass drug administration combinations for neglected tropical diseases (GRC-23-10-1093)","year":"2024","key":"pmed.1004736.ref026"},{"issue":"21","key":"pmed.1004736.ref027","first-page":"2060","article-title":"Azithromycin to reduce mortality","volume":"391","author":"M Goh","year":"2024","journal-title":"N Engl J Med"},{"volume-title":"AWaRe classification of antibiotics for evaluation and monitoring of use, 2023","year":"2023","author":"World Health Organization","key":"pmed.1004736.ref028"},{"issue":"12","key":"pmed.1004736.ref029","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cmi.2022.08.009","article-title":"The WHO essential medicines list AWaRe book: from a list to a quality improvement system","volume":"28","author":"M Sharland","year":"2022","journal-title":"Clin Microbiol Infect"},{"year":"2020","author":"AWaRe Portal","key":"pmed.1004736.ref030"},{"issue":"1","key":"pmed.1004736.ref031","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2023.164","article-title":"World Health Organization AWaRe framework for antibiotic stewardship: Where are we now and where do we need to go? An expert viewpoint","volume":"3","author":"S Mudenda","year":"2023","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"issue":"1","key":"pmed.1004736.ref032","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2024-002411","article-title":"Global trends in inappropriate use of antibiotics, 2000-2021: scoping review and prevalence estimates","volume":"3","author":"R Mulchandani","year":"2025","journal-title":"BMJ Public Health"},{"issue":"3","key":"pmed.1004736.ref033","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/mgmj.mgmj_6_21","article-title":"Impact of under-five mortality on economic growth and health-care expenditures in India","volume":"8","author":"S Chinnaiyan","year":"2021","journal-title":"MGM J Med Sci"},{"key":"pmed.1004736.ref034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.12688\/gatesopenres.12804.1","article-title":"Mortality, fertility, and economic development: an analysis of 201 countries from 1960 to 2015","volume":"2","author":"Q Li","year":"2018","journal-title":"Gates Open Res"},{"issue":"1","key":"pmed.1004736.ref035","doi-asserted-by":"crossref","DOI":"10.9734\/BJEMT\/2016\/22802","article-title":"Estimating the effect of maternal and child health outcomes to GDP per Capita","volume":"12","author":"J Trondillo","year":"2016","journal-title":"British J Econ Manag Trade"},{"issue":"4","key":"pmed.1004736.ref036","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ije\/dyx039","article-title":"Spillover effects on health outcomes in low- and middle-income countries: a systematic review","volume":"46","author":"J Benjamin-Chung","year":"2017","journal-title":"Int J Epidemiol"},{"edition":"2","volume-title":"WHO handbook for guideline development","year":"2014","key":"pmed.1004736.ref037"},{"issue":"10442","key":"pmed.1004736.ref038","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(24)00862-6","article-title":"Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis","volume":"403","author":"JA Lewnard","year":"2024","journal-title":"Lancet"},{"key":"pmed.1004736.ref039","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/00333549141291S206","article-title":"The social determinants of health: it\u2019s time to consider the causes of the causes","volume":"129","author":"P Braveman","year":"2014","journal-title":"Public Health Rep"},{"key":"pmed.1004736.ref040","doi-asserted-by":"crossref","DOI":"10.2471\/B09112","volume-title":"Addressing gender inequalities in national action plans on antimicrobial resistance: guidance to complement the people-centred approach","author":"World Health Organization","year":"2024"},{"issue":"1","key":"pmed.1004736.ref041","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-016711","article-title":"Understanding gender inequities in antimicrobial resistance: role of biology, behaviour and gender norms","volume":"10","author":"D Batheja","year":"2025","journal-title":"BMJ Glob Health"},{"issue":"1","key":"pmed.1004736.ref042","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmi.2014.10.013","article-title":"Ethical dilemmas in antibiotic treatment: focus on the elderly","volume":"21","author":"L Leibovici","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"pmed.1004736.ref043","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40592-024-00191-5","article-title":"Distributive justice and value trade-offs in antibiotic use in aged care settings","volume":"42","author":"J Williams","year":"2024","journal-title":"Monash Bioeth Rev"},{"key":"pmed.1004736.ref044","first-page":"169","volume-title":"One Health: a call for ecological equity","author":"The Lancet","year":"2023"},{"issue":"10376","key":"pmed.1004736.ref045","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0140-6736(23)00086-7","article-title":"One Health action for health security and equity","volume":"401","author":"One Health High-Level Expert Panel","year":"2023","journal-title":"Lancet"},{"key":"pmed.1004736.ref046","article-title":"GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"P Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"pmed.1004736.ref047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40592-024-00224-z","article-title":"Stewardship and social justice: implications of using the precautionary principle to justify burdensome antimicrobial stewardship measures","volume":"42","author":"T Johnson","year":"2024","journal-title":"Monash Bioeth Rev"},{"key":"pmed.1004736.ref048","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ebiom.2018.11.035","article-title":"Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: a double-blind, randomized, placebo-controlled trial","volume":"38","author":"S Wei","year":"2018","journal-title":"EBioMedicine"},{"key":"pmed.1004736.ref049","doi-asserted-by":"crossref","first-page":"756318","DOI":"10.3389\/fpubh.2022.756318","article-title":"Biannual administrations of azithromycin and the gastrointestinal microbiome of Malawian children: a nested cohort study within a randomized controlled trial","volume":"10","author":"D Chaima","year":"2022","journal-title":"Front Public Health"},{"key":"pmed.1004736.ref050","unstructured":"Pate MA, Sow SO. Abuja declaration on REACH for child survival: REACH. 2024. Available from: https:\/\/reachnetwork.africa\/en\/abuja-declaration\/"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T17:21:08Z","timestamp":1759252868000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004736","relation":{},"ISSN":["1549-1676"],"issn-type":[{"type":"electronic","value":"1549-1676"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}